A new enzyme immunoassay (EIA), PREMIER Cryptococcal Antigen, was compared with latex agglutination (LA) for the detection and quantitation of circulating capsular polysaccharide antigen from Cryptococcus neoformans. The clinical evaluation of PREMIER EIA as a screening assay, including 475 specimens with 120 LA and EIA positives, resulted in 99% sensitivity and 97% specificity. The clinical specimens included sera and cerebrospinal fluids as well as 10 rheumatoid factor-positive and 20 anti-nuclear antibody-positive serum samples. This monoclonal antibody-based assay detects serotypes A to D at 0.63, 0.63, 7.8, and 62 ng/ml, respectively. With three different known positive specimens, the assay was found to yield coefficients of variation of 2 to 12% for intra-and interassay comparisons of precision and reproducibility. The primary use for semiquantitative values derived with the LA or EIA is to follow the course of disease and monitor drug therapies. The present data suggest that the PREMIER EIA will be a valuable method for this purpose. We conclude that the PREMIER Cryptococcal Antigen EIA provides a rapid, convenient, and reliable antigen detection method for screening and semiquantitative determination of antigen levels.
Cryptococcus neoformans is an encapsulated yeast which frequently causes subclinical pulmonary infections in the immunocompetent host (10, 12, 13) . Cryptococcal infections are an increasingly important cause of meningeal complications in immunocompromised patients (12, 13). For example, cryptococcosis is now the fourth most common opportunistic infection in AIDS patients (12, 13). Although four major serotypes (A to D) of cryptococcal capsular polysaccharide antigen exist, serotypes A and B predominate (10) . Interestingly, cryptococcal isolates from AIDS patients have been almost exclusively of serotype A, even in Southern California where the serotype pair B and C is isolated more frequently from the general population (2) .
Traditionally, diagnosis of cryptococcal meningitis depends on culturing C. neoformans or the demonstration of encapsulated yeasts in India ink preparations from cerebrospinal fluid (CSF) (5, 7) . Detection of the capsular antigen in either serum or CSF has been established as a reliable additional means of diagnosis (1, 3, (5) (6) (7) . When both serum and CSF specimens are assayed for cryptococcal antigen, the sensitivity is well above 90% (7, 10) . Antigen detection is most often performed by latex agglutination (LA) assays (1, 5, 10, 12, 13) . The diagnostic and prognostic value of antigen detection and quantitation are well documented (1, 3, 10, 12, 13 ).
An enzyme immunoassay (EIA), the PREMIER Cryptococcal Antigen assay, has been developed for the detection of cryptococcal capsular polysaccharide antigen in either serum or CSF specimens. The assay utilizes a polyclonal capture system and a monoclonal detection system (4 The semiquantitative assay protocol requires that all reagents be dispensed with pipetters and that the two-vial substrate system be premixed immediately prior to the substrate incubation. Dilution of the specimen prior to assaying is required. Recommended dilutions include 100 ,ul of specimen and 100 ,ul of sample diluent, followed by a series of fivefold dilutions (50 p.l in 200 ,ul) in sample diluent.
The impact of interassay differences due to slight variations in protocol (e.g., incubation temperatures, incubation times, etc.) are minimized through the use of the control factor. The value of the control factor is calculated from the average of two positive control absorbance values.
Calculation of the EIA titer utilizes the following formula: absorbance x dilution factor x control factor = EIA titer.
Cross-reactivity. The mens. The other three EIA+/LA-specimens were considered false positives, since there was no other evidence of cryptococcal infection ( Table 2 ). Two of the 11 discordant results were indeterminant by the EIA; one was negative and one was positive by LA (insufficient specimen prevented retesting of these indeterminants). One of the 11 specimens was weakly positive with LA and negative with EIA. Clinical information was not available for this patient.
The EIA yielded negative results with all rheumatoid factor and anti-nuclear antibody serum samples. Following pronase treatment, all LA assays were also negative.
When specimen type is used as the basis for comparison, the screening assay results for 169 CSF and 304 serum samples are very similar. The sensitivity of the EIA screening assay with serum was 100% (95 of 95 LA positives), while the specificity was 97% (203 of 209 LA negatives). The sensitivity of the EIA with CSF was 96% (25 of 26 LA positives), and the specificity was 99% (141 of 143 LA negatives). The two indeterminant specimens were sera and are not included in the sensitivity and specificity calculations. The overall agreement between LA and the EIA was 98% with both sera and CSF.
Limits of detection of serotypes A to D. The limits of detection of the four major serotypes were determined for both LA and EIA. A series of twofold dilutions (in the respective sample diluents) was made from purified preparations of each serotype (11) . The limits of detection for the EIA were 0.63, 0.63, 15, and 62 ng/ml for serotypes A to D, respectively. This was compared with 7.6, 7.6, 15, and 61 ng/ml for serotypes A to D, respectively, for the LA assay. Thus, the EIA has a 12-fold sensitivity advantage over the LA for serotypes A and B and equivalent sensitivities for serotypes C and D.
EIA precision. The precision of the PREMIER EIA was determined by comparing the results of 16 replicates for three known positive samples. The coefficients of variation within the first run were 8.6, 2.1, and 2.2%. Interassay variation was determined by repeat assays of three samples (16 replicates of each sample, two operators, and two runs). The interassay variations were 7.2, 11.5, and 11.8%.
Comparison of semiquantitative results. Semiquantitative EIA and LA results from sequential specimens obtained from several patients were compared to determine if PRE-MIER EIA titers could be utilized to follow the course of disease and monitor drug therapies. Figure 1 shows data from two patients who were undergoing therapy for cryptococcal disease. Each serum sample was tested with both assays on the same date. All sera had been frozen between the date drawn and the date of testing. The results obtained from both LA and EIA of sequential specimens showed similar decreases in titer for patients A and B.
Comparison of serum and CSF antigen concentrations. When both serum and CSF were obtained from an individual on the same day, antigen levels were higher in the serum than the CSF. During the clinical trial, 10 such serum-CSF pairs were tested by both LA and EIA. Five pairs did not contain detectable antigen in either serum or CSF and were diagnosed as negative for cryptococcal disease. The other five paired specimens were obtained from four patients, all of whom had previously had positive CSF cultures for cryptococcus. All five pairs contained detectable serum antigen by both assays. However, antigen was detected in only four of these five CSF specimens by EIA and two of the five by LA. In three specimen pairs from an individual patient, the mean serum titers were 2,000 and 87,000 for LA and EIA, respectively. The corresponding mean CSF titers were 2 and 16 for LA and EIA, respectively. Specificity of the EIA. The EIA was tested with suspensions of 20 different microorganisms and 6 fungal antigen preparations, representing 26 organisms that may cause similar clinical symptoms or that may be found as contaminants in serum or CSF specimens. Table 3 illustrates the results when antigen preparations or suspensions of organisms were (i) substituted for the patient specimen and tested and (ii) mixed with a known quantity of cryptococcal antigen and tested. Only Trichosporon beigelii caused a false-positive reaction with the EIA, and this organism also causes false positives with the LA assay (8) . None of the other organisms or antigen preparations caused significant interference with the assay when mixed with a known quantity of cryptococcal antigen. (9) . However, this organism is an uncommon pathogen and is unlikely to cause frequent misdiagnoses with either assay (8) .
The use of EIA data for monitoring disease status and drug therapy was evaluated through the use of sequential serum samples from six individual patients. Data from two patients, illustrated in Fig. 1 , show similar trends in the amount of antigen detected with both assays. Both patients appear to be responding to therapy. Although more extensive evaluation of the EIA's value in monitoring sequential specimens is needed, the preliminary comparisons are encouraging.
It is noteworthy that the LA and PREMIER EIA titers are not numerically equivalent. In general, the EIA titers are slightly higher than LA titers for specimens with relatively low antigen concentrations. At higher antigen concentrations the EIA titers are frequently 20-to 100-fold higher than LA titers. Therefore, it is not advisable to convert EIA titers into LA titers. The data from sequential specimens from a single patient suggest that a similar trend will be observed with both assays, even though the actual numbers may be quite different.
We conclude that the PREMIER Cryptococcal Antigen EIA provides for direct specimen detection (without pronase or other pretreatment) in less than 45 min. PREMIER appears to have a 12-fold sensitivity advantage over LA for the two most common serotypes (A and B). The EIA is a simple, rapid, and reliable screening assay for the early detection of cryptococcal antigen in either serum or CSF. Preliminary data indicate that the semiquantitative assay may be a useful method of monitoring the efficacies of drug therapies. Prospective evaluation of the utility of the EIA for monitoring sequential specimens is ongoing.
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